Schiff R - Search Results

1

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Rimawi MF, et al. Among authors: schiff r. Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7. Clin Cancer Res. 2011. PMID: 21138857 Free PMC article.

2

Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.

Hilsenbeck SG, Friedrichs WE, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SA. Hilsenbeck SG, et al. Among authors: schiff r. J Natl Cancer Inst. 1999 Mar 3;91(5):453-9. doi: 10.1093/jnci/91.5.453. J Natl Cancer Inst. 1999. PMID: 10070945

3

Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer.

Fuqua SA, Schiff R, Parra I, Friedrichs WE, Su JL, McKee DD, Slentz-Kesler K, Moore LB, Willson TM, Moore JT. Fuqua SA, et al. Among authors: schiff r. Cancer Res. 1999 Nov 1;59(21):5425-8. Cancer Res. 1999. PMID: 10554010

4

Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.

Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Chamness GC, Fuqua SA, Brown PH, Osborne CK. Schiff R, et al. J Natl Cancer Inst. 2000 Dec 6;92(23):1926-34. doi: 10.1093/jnci/92.23.1926. J Natl Cancer Inst. 2000. PMID: 11106684

5

Estrogen receptor: current understanding of its activation and modulation.

Osborne CK, Schiff R, Fuqua SA, Shou J. Osborne CK, et al. Among authors: schiff r. Clin Cancer Res. 2001 Dec;7(12 Suppl):4338s-4342s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916222 Review.

6

Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth.

Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, Brown PH. Liu Y, et al. Among authors: schiff r. Oncogene. 2002 Oct 31;21(50):7680-9. doi: 10.1038/sj.onc.1205883. Oncogene. 2002. PMID: 12400010

7

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Schiff R, Massarweh S, Shou J, Osborne CK. Schiff R, et al. Clin Cancer Res. 2003 Jan;9(1 Pt 2):447S-54S. Clin Cancer Res. 2003. PMID: 12538499 Review.

8

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

Lee AV, Schiff R, Cui X, Sachdev D, Yee D, Gilmore AP, Streuli CH, Oesterreich S, Hadsell DL. Lee AV, et al. Among authors: schiff r. Clin Cancer Res. 2003 Jan;9(1 Pt 2):516S-23S. Clin Cancer Res. 2003. PMID: 12538509 Review.

9

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R. Osborne CK, et al. Among authors: schiff r. J Natl Cancer Inst. 2003 Mar 5;95(5):353-61. doi: 10.1093/jnci/95.5.353. J Natl Cancer Inst. 2003. PMID: 12618500

10

Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor.

Morrison AJ, Herrera RE, Heinsohn EC, Schiff R, Osborne CK. Morrison AJ, et al. Among authors: schiff r. Mol Endocrinol. 2003 Aug;17(8):1543-54. doi: 10.1210/me.2001-0144. Epub 2003 May 1. Mol Endocrinol. 2003. PMID: 12730327

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters